Abstract
The reaction of cyanoacetylhydrazine (1) with 3-(2-bromoacetyl)-2H-chromen-2-one (2) in 1,4-dioxan gave the hydrazidehydrazone derivative (3). The latter compound was cyclized to the 1,3,4-oxadiazine derivative 4, its 4-bromo derivative underwent a series of cross coupling reactions together with [4+2] cycloaddition reactions with either acrylonitrile or ethyl acrylate to afford the pyran derivatives 10a and 10b, respectively. The antitumor evaluation of the newly synthesized products against three cancer cell lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were recorded. Four of the synthesized compounds namely 7c, 10a, 11a and 12b showed high inhibitory effects. Moreover, the anti-leishmanial activity of the newly synthesized product was tested on Leishmania donovani amastigotes showed that some compounds have high activity.
Keywords: Cross coupling, Hydrazide-hydrazone, 1, 3, 4-oxadiazine, coumarin, Anti-tumor.
Current Organic Chemistry
Title:Design, Synthesis and Molecular Modeling Studies of Some Heterocyclic Compounds Derived from the Suzuki-coupling of 6-bromo-1,3,4-oxadiazine Together with their Antitumor and Anti-leishmanial Evaluations
Volume: 17 Issue: 17
Author(s): Rafat M. Mohareb, Sherif M. Sherif and Adel Abou Elkair
Affiliation:
Keywords: Cross coupling, Hydrazide-hydrazone, 1, 3, 4-oxadiazine, coumarin, Anti-tumor.
Abstract: The reaction of cyanoacetylhydrazine (1) with 3-(2-bromoacetyl)-2H-chromen-2-one (2) in 1,4-dioxan gave the hydrazidehydrazone derivative (3). The latter compound was cyclized to the 1,3,4-oxadiazine derivative 4, its 4-bromo derivative underwent a series of cross coupling reactions together with [4+2] cycloaddition reactions with either acrylonitrile or ethyl acrylate to afford the pyran derivatives 10a and 10b, respectively. The antitumor evaluation of the newly synthesized products against three cancer cell lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were recorded. Four of the synthesized compounds namely 7c, 10a, 11a and 12b showed high inhibitory effects. Moreover, the anti-leishmanial activity of the newly synthesized product was tested on Leishmania donovani amastigotes showed that some compounds have high activity.
Export Options
About this article
Cite this article as:
Mohareb M. Rafat, Sherif M. Sherif and Elkair Abou Adel, Design, Synthesis and Molecular Modeling Studies of Some Heterocyclic Compounds Derived from the Suzuki-coupling of 6-bromo-1,3,4-oxadiazine Together with their Antitumor and Anti-leishmanial Evaluations, Current Organic Chemistry 2013; 17 (17) . https://dx.doi.org/10.2174/13852728113179990037
DOI https://dx.doi.org/10.2174/13852728113179990037 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery Recent Development of Drug Delivery Systems for the Treatment of Asthma and Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Osteopontin: An Effector and an Effect of Tumor Metastasis
Current Molecular Medicine New Concepts for Glaucoma Implants - Controlled Aqueous Humor Drainage, Encapsulation Prevention and Local Drug Delivery
Current Pharmaceutical Biotechnology Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance
Mini-Reviews in Medicinal Chemistry Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
Current Cancer Drug Targets General Principles for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Rho-Signaling Pathways in Chronic Myelogenous Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment
Combinatorial Chemistry & High Throughput Screening Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design Imaging Conditions Optimization of Human Bronchial Epithelial Cell Based on Atomic Force Microscope
Current Nanoscience The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Antiproliferative Evaluation of Spirothiadiazolopyridazine Derivatives
Letters in Drug Design & Discovery Structure, Function and Inhibition of Bcl-2 Family Proteins: A New Target for Anti-Tumor Agents
Mini-Reviews in Medicinal Chemistry Therapeutic Perspectives on Pancreatic Cancer
Current Cancer Drug Targets nMET, A New Target in Recurrent Cancer
Current Cancer Drug Targets Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Current Genomics Meet Our Editor:
MicroRNA